Favourable Outcomes for Carfilzomib-Melphalan and Bortezomib-Melphalan Conditioned Autologous Hematopoietic Stem Cell (AHCT) Transplants in Relapsed/Primary Refractory Myeloma: An Australian Single Centre Real-World Experience
Despite improvements in the treatment options for myeloma, transplant eligible patients with primary refractory or relapsed disease have inferior outcomes. As there is evidence for synergy and safety for the combination of proteasome inhibitors and melphalan, bortezomib or carfilzomib is added to melphalan conditioning for these high-risk patients prior to AHCT in our institution.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Brydon Panozzo, Jeremy Er, David Routledge, Trish Joyce, Simon J Harrison, Amit Khot Tags: 529 Source Type: research
More News: Australia Health | Biology | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Transplants | Velcade